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effect. Therefore it is impossible to set a certain Hounsﬁeld value as a 
threshold for potential nodule.
With the advent of multi-slice CT the quality of image has been 
considerably improved over that of conventional CT with thick slices, 
thus the performance of CAD schemes in the detection of nodules on 
MDCT has generally been improved. At ﬁrst high resolution CT was 
used mainly for segmentation, characterisation and classiﬁcation of 
already identiﬁed nodules. More recently HRCT data have also been 
used for nodule detection. The sensitivity of CAD system alone has 
been assessed with reported sensitiveness up to 84%. One of the best 
performance of a lung nodule CAD system (Philips Research, Ham-
burg, Germany) has been recently reported by Wiemker et al. on a pilot 
study conducted in the years 2000-2001 by a 4-slice scanner over the 
entire thorax at 120 kV and 100 mAs with a slice thickness of 1 mm. In 
addition to the radiologist, the thoracic data sets were read by the CAD 
software (computation time was approximately 1 min for all 300-500 
slices per thorax). The automated detection showed a sensitivity of 
84% (detection rate including nodules of all sizes). If the minimum 
nodule size for detection was set to 2 mm, the sensitivity was 95% with 
4.4 false positives per patient. Although these are encouraging results, 
such a high detection rate at an equally low false positive rate can not 
be expected in all clinical settings. For example examinations may be 
taken with low dose imaging protocols. 
In our Institute we recently tested the performances of two different 
CADs for the detection of lung nodules (i.e. diameter > 6 mm) and 
early stage lung cancers using low-dose CT of the lung. All low-dose 
CT scans were obtained with a 8- or 16-section CT scanner (General 
Electric, Milwaukee, WI, USA) with the following parameters: 140 
kVp, 30 mA, 1.75:1 pitch ratio, and 2.5 mm slice thickness. Native 
DICOM images were sent and processed using two different CAD 
systems (LMS-Lung, MedianTechnologies and Lung VCARE, General 
Electric Medical System). Both CAD systems, applying multiple and 
different algorithms, automatically detect and segment potential regions 
of interest that are marked on CT scan. Each mark were subsequently 
accepted or refused by radiologists, mentioning results in a written 
report. Accepted nodules were automatically extracted using a 3D-
template method. Image data have been extracted from our data-base 
of 16.000 low-dose CT. The scan of a series of 90 patients with lung 
cancer and a series of 90 subjects with at least one benign lung nodule 
> 5 mm (conﬁrmed by at least 1-year follow-up) have been selected 
and the results of CAD analysis have been compared with the diagnosis 
made by the expert Radiologist before and after consideration of the 
CAD results to obtain true and false positive and negative results. The 
preliminary results of the study have demonstrated a relatively low sen-
sitivity for both CAD systems alone (less than 60%) but a signiﬁcant 
role of CAD as a second reader in increasing the detection rate of the 
radiologists with a limited rate of false positives per scan (0.7-1.5).
In conclusion, with the excellent spatial resolution of modern mul-
tislice CT scanners and their ability to acquire a thoracic scan within 
one breath-hold, software algorithms for computer-aided detection 
(CAD) of pulmonary nodules are now reaching high sensitivity levels 
at moderate false positive rates. A number of pilot studies have shown 
that CAD modules can successfully ﬁnd overlooked pulmonary nodules 
and serve as a powerful tool for diagnostic quality assurance. Equally 
important are tools for fast and accurate three-dimensional volume 
measurement of detected nodules. These allow monitoring of nodule 
growth between follow-up examinations for differential diagnosis and 
response to oncological therapy. Owing to decreasing partial volume 
effect, nodule volumetry is more accurate with high resolution CT data.
The current results obtained from research of CAD may be considered 
the tip of a iceberg and a major impact of CAD on medical imaging and 
diagnostic radiology maybe expected in the future.
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Solitary pulmonary opacities are common and the increasing use of CT 
together with improvements in CT image acquisition and quality has 
resulted in a high incidence of detection. Most incidentally discovered 
nodules are benign and despite an extensive differential diagnosis are 
usually the sequelae of pulmonary infection. Nevertheless, a signiﬁcant 
proportion of lung cancers manifest as solitary pulmonary opacities. 
Because the prognosis of lung cancer depends on a number of factors 
including stage at presentation, there is an emphasis on early diagnosis 
and consequently CT and positron emission tomography (PET) imag-
ing are often used to evaluate focal pulmonary opacities.
CT optimally evaluates the growth rate and morphological character-
istics (size, margins, contour, internal morphology) that can be useful 
in distinguishing benign from malignant nodules. CT is the modality 
of choice in the assessment of a nodules growth rate and it is generally 
accepted that the absence of visible growth over a 2-year period is reli-
able in determining benignity. However, in a screening study analyzing 
the growth rates of small lung cancers, it was found that approximately 
20% of these opacities had a volumetric doubling time greater than 
2 years. The concern raised about conferring benignity to a lesion 
based on the absence of growth over 2 years is particularly important 
when the accuracy of growth assessment in small nodules is consid-
ered. However, the use of CT does in most cases allows an accurate 
assessment of growth and it has been recently reported that growth 
can be detected in lung cancers as small as 5 mm when CT imaging is 
repeated within a 30 day interval. Furthermore, the measurement of se-
rial volumes, rather than diameters, and computer calculated doubling 
of volume of small nodules has been suggested to be an accurate and 
potentially useful method to assess growth. 
In terms of morphology, the likelihood of malignancy increases the 
larger the opacity is. However, the widespread use and improvements 
in CT, coupled with CT screening for lung cancer, has resulted in the 
frequent detection small nodules. While the majority of these nodules 
are benign, small size does not exclude malignancy. The margin and 
contour of a solitary pulmonary opacity can also be used to distinguish-
ing benign from malignant nodules: benign nodules typically have 
well-deﬁned margins and a smooth contour while malignant nodules 
have poorly deﬁned or spiculated margins and a lobular or irregular 
contour. However, there is considerable overlap between benign and 
malignant nodules regarding margins and contour and up to 20% of pri-
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mary lung malignancies have smooth contours. Internal morphology of 
a nodule, with the exception of fat and calciﬁcation, is unreliable in dis-
tinguishing a malignant from a benign nodule. In terms of calciﬁcation, 
the majority of benign nodules are not calciﬁed. However, the presence 
of diffusely solid, centrally punctate and laminated calciﬁcation can be 
useful in determining benignity of a nodule. The widespread use of thin 
collimation CT images has increased the detection of nodules with low 
attenuation (non-solid or ground-glass, partially solid, solid). Impor-
tantly, the incidence of malignancy varies according to the degree of 
soft tissue attenuation. Partially solid nodular opacities have the highest 
incidence of malignancy with an incidence of malignancy of 40-50% 
in lesions less than 1.5 cm. Nodular opacities with solid attenuation 
have the lowest incidence of malignancy, as many infections manifest 
as solid nodules. However, despite the lower incidence of malignancy 
in solid nodules, most primary lung cancers and metastases manifest as 
solid nodules. 
Contrast-enhanced CT can be used to differentiate between benign 
and malignant nodules because the perfusion of malignant pulmonary 
nodules is qualitatively and quantitatively different from that of benign 
nodules. The intensity of enhancement is directly related to the vascu-
larity of the nodule, which is increased in malignant nodules. Contrast-
enhanced CT has been shown in a multi-institutional prospective trial 
to be useful in determining the likelihood of malignancy of nodules 
that are indeterminate in etiology after standard radiological evaluation. 
Typically, malignant nodules enhance more than 20 HU, while benign 
nodules enhance less than 15 HU. 
PET can be used as an additional study to evaluate a solitary pulmo-
nary opacity detected radiologically or as an alternative to contrast-
enhanced CT to differentiate benign from malignant nodules. Similar 
to contrast enhancement, metabolism of glucose is typically increased 
in malignant nodules compared to benign nodules. PET, using the D-
glucose analog 18F-labeled 2-deoxy-D-glucose (FDG), can be used to 
image this increase in glucose metabolism, allowing differentiation of 
malignant from benign nodules. FDG uptake can be assessed visually 
on PET images by comparing the activity of the lesion with that of the 
background or by semi-quantitative analysis using calculated standard-
ized uptake values (SUV). A standardized uptake ratio of > 2.5 is gen-
erally considered to be indicative of malignancy. In a meta-analysis of 
forty studies FDG-PET was found to operate at a point on the summary 
receiver operating characteristic curve corresponding to a sensitivity 
of 96.8% and speciﬁcity of 78%. It is important to emphasize that the 
published data regarding FDG-PET evaluation of solitary pulmonary 
opacities indicating high sensitivity, speciﬁcity and accuracy mostly 
pertains to nodules that are both solid and 1 cm or greater in diameter. 
The probability of malignancy is high when a solid nodule of 1 cm or 
greater has increased FDG uptake but benign neoplasms and nodules 
due to infection and inﬂammation can result in false-positive diagno-
ses. When FDG uptake by a solid nodule 1 cm or greater in diameter 
is low, the likelihood of malignancy is generally considered to be low. 
However, in a recent study of 360 patients with lung nodules evaluated 
by FDG-PET, 43 patients had solid nodules with an SUV > 2.5, 16 of 
which were malignant. In an attempt to detect those malignant nodules 
falsely designated benign after FDG-PET, radiologic follow-up, biopsy 
or resection as can be performed according to the recommendations 
of the Fleischner Society for the management of pulmonary nodules 
discovered incidentally on routine and screening CT. In malignant 
nodules that are smaller than 1 cm in diameter or have ground glass 
or partially solid morphology, FDG-uptake is variable and unreliable 
in differentiating benign from malignant nodular opacities. Limita-
tions in spatial resolution can also result in false-negative studies when 
nodules smaller than 1 cm in diameter are evaluated. Although there is 
little published data to determine the appropriate role of FDG-PET in 
the evaluation of nodules < 1-cm in diameter, in general, because the 
resolution of PET scanners is in the order of 5-mm, FDG-PET is not 
recommended in the routine evaluation of small nodules.
Integrated PET-CT scanners allow the near-simultaneous acquisition of 
co-registered, spatially matched functional and morphologic data. The 
temporal and spatial fusion of these two sets of images can be useful 
when used as the initial imaging modality in nodule characterization 
(sensitivity 96%, accuracy 93% vs. 81%, 85% for CT. However, a 
recent prospective integrated PET-CT evaluation of 585 patients (496 
malignant, 89 benign nodules) showed that although a high SUV (> 
4.1) was associated with a 96% likelihood of malignancy, if the SUV 
was 0-2.5, the likelihood of malignancy was 25%. The usefulness of 
FDG-PET in determining whether a solitary pulmonary opacity is a 
NSCLC is not predicated on diagnostic accuracy alone, but also on 
clinical risk factors for malignancy, the radiologic appearance of the 
opacity and how patient management will be altered. For instance in a 
patient with a low pretest likelihood of malignancy (20%), a negative 
PET will reduce the likelihood of malignancy to 1% and thereby justify 
conservative management. However, in a patient with a high pretest 
likelihood of malignancy (80%) a negative PET will only reduce the 
likelihood of malignancy to 14%. 
In summary, solitary pulmonary opacities are common and are often 
detected incidentally. The goal of management is to correctly differenti-
ate malignant from benign opacities so that appropriate treatment can 
be initiated. Although there is considerable overlap in the characteris-
tics of benign and malignant solitary pulmonary opacities the use of 
CT for the detection of speciﬁc patterns of calciﬁcation and stability in 
size for 2 years or more can be useful in determining benignity. More 
recently, the ability to distinguish benign and malignant opacities has 
improved with assessment of nodule perfusion and metabolism using 
contrast-enhanced CT and FDG CT-PET imaging, respectively.
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Ground-glass opacity is characterized as a hazy increase in lung density 
on HRCT that is not associated with obscuration of underlying vessels 
and can be differentiated from airspace consolidation or solid nodule. 
Pathologically the lesion showing GGO must contain air in the voxel 
on the each CT slice. Considering volume averaging phenomenon, 
thick collimation is much less speciﬁc to assess the GGO especially in 
the lesion of the small nodules. Therefore, this term must be applied 
only to HRCT less than 2 mm in collimation(1).
1, GGO and differential diagnosis, benign vs. malignant
The most reliable indicator for differentiation between benign and ma-
lignancy is the size of the nodule and it’s interval change (2.) .From the 
Mayo clinic CT screening trial, a likelihood of malignancy is a 0.9% 
for nodules smaller than 7 mm, 18% for those 8-20 mm, and 50% for 
those larger than 20 mm (3). Interval size change is widely used stan-
dard of practice that any non-calciﬁed pulmonary nodules with stable 
over 2 years could be a benign nature (4, 5). 
Recent advance in cancer screening with CT in Japan, US and some 
other countries has enabled us to ﬁnd small pulmonary nodules. Also 
